AXIM Biotechnologies, Inc. (AXIM)
| Market Cap | 5.41M |
| Revenue (ttm) | 6,123 |
| Net Income (ttm) | -13.39M |
| Shares Out | 186.44M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500,490 |
| Open | 0.0270 |
| Previous Close | 0.0296 |
| Day's Range | 0.0253 - 0.0290 |
| 52-Week Range | 0.0200 - 0.2800 |
| Beta | 1.54 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AXIM
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid q... [Read more]
Financial Performance
Financial StatementsNews
AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye ...
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Com...
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM's Eye Diagnostic Solutions
Technology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets' Coverage of Innovative Diagnostic Solutions Technology and Benefits Company At Forefront of Leading Ophthalmolog...
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company Healthcare Solutions Company Receives Initial ...
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics' Commercial Launch at AAO 2022
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership Sales of Point-of-Care Diagnostic Test...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
Under the Agreement the Company will Sell and Distribute Globally AXIM's Readers and Three Novel Proprietary Tests Designed for Diagnosis of Dry Eye Disease Under the Agreement the Company will Sell a...
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their pub...
AXIM Launches New Eye Care Website; Establishes Platform for Commercialization
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface d...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface di...
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Dise...
AXIM Biotechnologies CEO Issues Letter to Shareholders
AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease ...
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnos...
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
Company's first rapid test to measure neutralizing antibodies is currently under FDA review Company's first rapid test to measure neutralizing antibodies is currently under FDA review
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
Company develops COVID-19 “Correlate of Protection” research to measure levels of neutralizing antibodies which protect from infection Company develops COVID-19 “Correlate of Protection” research to m...
AXIM Biotechnologies' Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
Publication in the Journal of Clinical Virology Highlights Effectiveness of the Rapid Test To Identifying Immunity Levels of Functional Antibodies, Preventing the Virus from Infecting Cells Publicatio...
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19...
AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board
Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COV...
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board